Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression

Journal of Infectious Diseases

Volumn 203, Issue 5, 2011, Pages 715-725

  Makala, Levi H C ^a   Baban, Babak ^a   Lemos, Henrique ^a   El Awady, Ahmed R ^a   Chandler, Phillip R ^a   Hou, De Yan ^a   Munn, David H ^a   Mellor, Andrew L ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERLEUKIN 17; PARASITE ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; HOST; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; INNATE IMMUNITY; LEISHMANIA MAJOR; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN LEISHMANIASIS; T LYMPHOCYTE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; HOST-PARASITE INTERACTIONS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKINS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPH NODES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTE SUBSETS;

EID: 79751504300     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq095     Document Type: Article

References (42)

1. Peters N, Sacks D. Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunolo Rev 2006; 213:159-79. (Pubitemid 44401500)
2. Liese J, Schleicher U, Bogdan C. The innate immune response against Leishmania parasites. Immunobiology 2008; 213:377-87.
3. Sharma U, Singh S. Immunobiology of leishmaniasis. Indian J Exp Biol 2009; 47:412-23.
4. Moll H, Rollinghoff M. Resistance to murine cutaneous leishmaniasis is mediated by TH1 cells, but disease-promoting CD4+ cells are different from TH2 cells. Eur J Immunol 1990; 20:2067-74. (Pubitemid 20355631)
5. Lohoff M, Sommer F, Solbach W, Rollinghoff M. Coexistence of antigen-specific TH1 and TH2 cells in genetically susceptible BALB/c mice infected with Leishmania major. Immunobiology 1989; 179:412-21. (Pubitemid 19268315)
6. Locksley RM, Heinzel FP, Holaday BJ, Mutha SS, Reiner SL, Sadick MD. Induction of Th1 and Th2 CD4+ subsets during murine Leishmania major infection. Res Immunol 1991; 142:28-32.
7. Scott P. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol 1991; 147:3149-55.
8. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988; 168:1675-84. (Pubitemid 19023255)
9. Holaday BJ, Sadick MD, Wang ZE, et al. Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines. J Immunol 1991; 147:1653-8.
10. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995; 13:151-77.
11. Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y. Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med 2006; 203:777-88.
12. Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism interactions (*). Annu Rev Immunol 2009; 27:551-89.
13. Belkaid Y, Tarbell KV. Arming Treg cells at the inflammatory site. Immunity 2009; 30:322-3.
14. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008; 8:74-80.
15. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114:280-90. (Pubitemid 39071633)
16. Sharma MD, Baban B, Chandler PR, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117:1-13.
17. Muller AJ, Sharma MD, Chandler PR, et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A 2008; 105:17073-8.
18. Hou D, Muller AJ, Sharma M, Mellor AL, Prendergast GC, Munn DH. Stereoisomers of 1-methyl-tryptophan as pharmacologic inhibitors of indoleamine 2,3-dioxygenase. Cancer Res 2007; 67:792-801. (Pubitemid 46192220)
19. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009; 183:2475-83.
20. Sharma MD, Hou D-Y, Liu Y, et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009; 113:6102-11.
21. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH. Cutting edge: CpG Oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J Immunol 2005; 175:5601-5. (Pubitemid 41508038)
22. Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol 2004; 61:67-77. (Pubitemid 38446980)
23. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22:329-41. (Pubitemid 40387475)
24. Belkaid Y, Kamhawi S, Modi G, et al. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 1998; 188:1941-53. (Pubitemid 28536781)
25. Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G, Sacks D. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 2000; 165:969-77.
26. Belkaid Y, Von Stebut E, Mendez S, et al. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 2002; 168:3992-4000. (Pubitemid 34298404)
27. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420:502-7. (Pubitemid 35477041)
28. Mellor AL, Baban B, Chandler P, et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003; 171:1652-5. (Pubitemid 36966447)
29. Baban B, Hansen AM, Chandler PR, et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol 2005; 17:909-19.
30. Bertholet S, Debrabant A, Afrin F, et al. Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells. Infect Immun 2005; 73:6620-8. (Pubitemid 41372127)
31. Johnson BA, Kahler DJ, Baban B, et al. -lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. U S A 2010; 107:10644-48.
32. Anderson CF, Stumhofer JS, Hunter CA, Sacks D. IL-27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J Immunol 2009; 183:4619-27.
33. Lopez Kostka S, Dinges S, Griewank K, Iwakura Y, Udey MC, von Stebut E. IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J Immunol 2009; 182:3039-46.
34. Johnson BA, Baban B, Mellor AL. Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy 2009; 1:645-61.
35. Yurchenko E, Tritt M, Hay V, Shevach EM, Belkaid Y, Piccirillo CA. CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J Exp Med 2006; 203:2451-60. (Pubitemid 44664615)
36. Bourreau E, Ronet C, Darcissac E, et al. Intralesional regulatory T-cell suppressive function during human acute and chronic cutaneous leishmaniasis due to Leishmania guyanensis. Infect Immun 2009; 77:1465-74.
37. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004; 10:15-8. (Pubitemid 38165324)
38. van der Sluijs KF, Nijhuis M, Levels JH, et al. Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J Infect Dis 2006; 193:214-22. (Pubitemid 43113483)
39. Popov A, Abdullah Z, Wickenhauser C, et al. Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J Clin Invest 2006; 116:3160-70. (Pubitemid 44878630)
40. Almeida AS, Lago PM, Boechat N, et al. Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J Immunol 2009; 183:718-31.
41. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999; 20:469-73.
42. Zelante T, Fallarino F, Bistoni F, Puccetti P, Romani L. Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host. Microbes Infect 2009; 11:133-41.